社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Pacira Pharmaceuticals(PCRX)
盘后
36.42
0.00
0.00%
19:30 EDT
36.42
+0.08
+0.22%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
公司概况
公司名称
Pacira Pharmaceuticals
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.pacira.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Pacira BioSciences, Inc.成立于2006年12月，自2007年3月以来一直在开展与EXPAREL相关的业务。该公司是一家专注于开发、商业化和制造医药产品的专业制药公司，基于公司专有的DepoFoam给药技术，主要用于医院和门诊手术中心。该公司经营一个可报告的分部。2011年10月28日，美国食品药品监督管理局（FDA）批准了公司的新药申请，即NDA，用于公司的主要候选产品EXPAREL，一种布比卡因的脂质体注射液，一种适用于浸润到手术部位以产生术后镇痛长达72小时的酰胺型局部麻醉剂。该公司认为，EXPAREL解决了对长效非阿片类术后镇痛剂的重大未满足的医疗需求，从而简化了术后疼痛管理并减少了阿片类药物的消耗，从而改善了患者的治疗效果并提高了医院经济效益。公司发展了一支完全致力于将EXPAREL商业化的内部销售队伍，公司于2012年4月将其商业化推出。此外，继试点计划后，自2013年10月1日起，公司任命CrossLink BioScience，LLC或CrossLink作为独家第三方分销商，为期五年，在美国推广和销售用于骨科和脊柱手术的EXPAREL，但某些地理区域和账户除外，可能会根据双方协议进行变更和调整。
10-08
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
10-08
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
08-17
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
08-07
超过5%披露
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
08-04
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08-04
员工持股计划
Form S-8 - Securities to be offered to employees in employee benefit plans
Form S-8 - Securities to be offered to employees in employee benefit plans
08-04
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
06-30
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
06-12
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
06-11
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
06-11
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
06-04
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
05-01
超过5%披露
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
05-01
超过5%披露
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
04-30
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
分时
5日
日
周
月
数据加载中...
最高
36.42
今开
36.33
量比
0.51
最低
36.33
昨收
36.34
换手率
1.47%
热议股票
{"pagemeta":{"title":"Pacira Pharmaceuticals(PCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Pacira Pharmaceuticals(PCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Pacira Pharmaceuticals,PCRX,Pacira Pharmaceuticals股票,Pacira Pharmaceuticals股票老虎,Pacira Pharmaceuticals股票老虎国际,Pacira Pharmaceuticals行情,Pacira Pharmaceuticals股票行情,Pacira Pharmaceuticals股价,Pacira Pharmaceuticals股市,Pacira Pharmaceuticals股票价格,Pacira Pharmaceuticals股票交易,Pacira Pharmaceuticals股票购买,Pacira Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pacira Pharmaceuticals(PCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Pacira Pharmaceuticals(PCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"summary","symbol":"PCRX","data":{"stockData":{"symbol":"PCRX","market":"US","secType":"STK","nameCN":"Pacira Pharmaceuticals","latestPrice":36.42,"timestamp":1792785600000,"preClose":36.34,"halted":0,"volume":574317,"hourTrading":{"tag":"盘后","latestPrice":36.42,"preClose":36.42,"latestTime":"19:30 EDT","volume":13172,"amount":479496.22,"timestamp":1792798204852,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0022014309301045206,"floatShares":39180600,"shares":39861886,"eps":0.351765,"marketStatus":"休市中","change":0.08,"latestTime":"10-23 16:00:00 EDT","open":36.33,"high":36.42,"low":36.33,"amount":20888438.810274,"amplitude":0.002477,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.351765,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1296709200000,"exchange":"NASDAQ","adjPreClose":36.34,"preHourTrading":{"tag":"盘前","latestPrice":36.3,"preClose":36.34,"latestTime":"09:25 EDT","volume":2038,"amount":73866.18094800001,"timestamp":1792761900053,"change":-0.04,"changeRate":-0.001101,"amplitude":0.022014},"postHourTrading":{"tag":"盘后","latestPrice":36.42,"preClose":36.42,"latestTime":"19:30 EDT","volume":13172,"amount":479496.22,"timestamp":1792798204852,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5114561723095125,"impliedVol":0.0636,"impliedVolPercentile":0.008},"tweetData":null,"newsData":null,"noticeData":{"listData":[{"cdn_pdf":false,"hasAttachments":true,"id":"21842075","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326007312-PCRX","pdf_url":"","pub_time":1791432000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"PCRX","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000195917326007312/0001959173-26-007312-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000195917326007312/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILE2DxQrzVYvHVcidYP","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-10-08 12:00","pubTimestamp":1791432000,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21842010","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465926114571-PCRX","pdf_url":"","pub_time":1791432000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"PCRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/0001104659-26-114571-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EXHIBIT 2.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/tm2627240d2_ex2-1.htm","primary":true,"translateUrl":"","linkName":"tm2627240d2_ex2-1.htm","type":"EX-2.1","id":"NTFILEDgChxtQpj927jciZ","market":"us","size":603593},{"description":"FORM 8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/tm2627240d2_8k.htm","primary":false,"translateUrl":"","linkName":"tm2627240d2_8k.htm","type":"8-K","id":"NTFILE3KXaVujNm1ma96Ub","market":"us","size":53654},{"description":"EXHIBIT 99.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/tm2627240d2_ex99-1.htm","primary":false,"translateUrl":"","linkName":"tm2627240d2_ex99-1.htm","type":"EX-99.1","id":"NTFILEDZYSRrpHGRYVC81p","market":"us","size":89465},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/tm2627240d2_8kimg01.jpg","primary":false,"translateUrl":"","linkName":"tm2627240d2_8kimg01.jpg","type":"GRAPHIC","id":"NTFILEGX7AyrVmNuXeqsCG","market":"us","size":12627},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/tm2627240d2_8kimg02.jpg","primary":false,"translateUrl":"","linkName":"tm2627240d2_8kimg02.jpg","type":"GRAPHIC","id":"NTFILEFKnmUWeioXF8dDgM","market":"us","size":4973}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-10-08 12:00","pubTimestamp":1791432000,"title_zh":"Form 8-K - Current report","summary_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"项目1.01：签订实质性最终协议；项目7.01：法规FD披露；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21627433","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326006073-PCRX","pdf_url":"","pub_time":1786939200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"PCRX","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000195917326006073/0001959173-26-006073-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000195917326006073/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEhSPNRydjBwwJp2wG","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-08-17 12:00","pubTimestamp":1786939200,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21591342","market":"us","labels":[],"media":"sec.gov","original_id":"AN9375126000517-PCRX","pdf_url":"","pub_time":1786075200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","symbol":"PCRX","title":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","titleType":"超过5%披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000009375126000517/0000093751-26-000517-index.htm","us_notice_code":"Form SCHEDULE 13G","us_title_en":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/93751/000009375126000517/xslSCHEDULE_13G_X02/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"SCHEDULE 13G","id":"NTFILEBCrqrf5qqBvrkyRU","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"超过5%披露","pubTime":"2026-08-07 12:00","pubTimestamp":1786075200,"title_zh":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21575132","market":"us","labels":[],"media":"sec.gov","original_id":"AN162828026052635-PCRX","pdf_url":"","pub_time":1785816000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"PCRX","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/0001628280-26-052635-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q - PCRX - 06.30.2026","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/pcrx-20260630.htm","primary":true,"translateUrl":"","linkName":"pcrx-20260630.htm","type":"10-Q","id":"NTFILEAWTZS7vQPj6RU2Gq","market":"us","size":1741910},{"description":"EX-2.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/pcrx-06302026xex21.htm","primary":false,"translateUrl":"","linkName":"pcrx-06302026xex21.htm","type":"EX-2.1","id":"NTFILE5xeHfoZGNsdF6mpK","market":"us","size":1002898},{"description":"EX-10.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/ex101teehanexecutiveagreem.htm","primary":false,"translateUrl":"","linkName":"ex101teehanexecutiveagreem.htm","type":"EX-10.1","id":"NTFILE7KiHqgA4Mu6W88jP","market":"us","size":105542},{"description":"EX-31.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/pcrx-06302026xex311.htm","primary":false,"translateUrl":"","linkName":"pcrx-06302026xex311.htm","type":"EX-31.1","id":"NTFILEGsSwESuSdbC1mSwz","market":"us","size":11724},{"description":"EX-31.2","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/pcrx-06302026xex312.htm","primary":false,"translateUrl":"","linkName":"pcrx-06302026xex312.htm","type":"EX-31.2","id":"NTFILE9vZtHJ5mXdbTn8LB","market":"us","size":11699},{"description":"EX-32.1","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/pcrx-06302026xex321.htm","primary":false,"translateUrl":"","linkName":"pcrx-06302026xex321.htm","type":"EX-32.1","id":"NTFILEFxpM2bGwk2VoQfqh","market":"us","size":8309},{"description":"PACIRA BIOSCIENCES LOGO","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/pcrx-20260630_g1.jpg","primary":false,"translateUrl":"","linkName":"pcrx-20260630_g1.jpg","type":"GRAPHIC","id":"NTFILE317krBfPb6k3Ri9n","market":"us","size":468777},{"description":"PRODUCT PIPELINE","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/pcrx-20260630_g2.gif","primary":false,"translateUrl":"","linkName":"pcrx-20260630_g2.gif","type":"GRAPHIC","id":"NTFILEJ6yd5BHYkdqpLXgD","market":"us","size":218330}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2026-08-04 12:00","pubTimestamp":1785816000,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21575122","market":"us","labels":[],"media":"sec.gov","original_id":"AN162828026052724-PCRX","pdf_url":"","pub_time":1785816000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form S-8 - Securities to be offered to employees in employee benefit plans","symbol":"PCRX","title":"Form S-8 - Securities to be offered to employees in employee benefit plans","titleType":"员工持股计划","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052724/0001628280-26-052724-index.htm","us_notice_code":"Form S-8","us_title_en":"Form S-8 - Securities to be offered to employees in employee benefit plans","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"S-8","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052724/s-8esppplanregistrationaug.htm","primary":true,"translateUrl":"","linkName":"s-8esppplanregistrationaug.htm","type":"S-8","id":"NTFILE3VMn6mow2umvWhb9","market":"us","size":51056},{"description":"EX-FILING FEES","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052724/exfilingfees.htm","primary":false,"translateUrl":"","linkName":"exfilingfees.htm","type":"EX-FILING FEES","id":"NTFILE6XmBwUvS8W2qdxyo","market":"us","size":19515},{"description":"EX-5.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052724/s-8exhibit51august2026.htm","primary":false,"translateUrl":"","linkName":"s-8exhibit51august2026.htm","type":"EX-5.1","id":"NTFILE8FrUNHjXvDViQtyZ","market":"us","size":5634},{"description":"EX-23.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052724/s-8exhibit231august2026.htm","primary":false,"translateUrl":"","linkName":"s-8exhibit231august2026.htm","type":"EX-23.1","id":"NTFILE66zeTVZto44sZrA7","market":"us","size":1904},{"description":"ASHURST PERKINS COIE LETTERHEAD","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052724/ashurstperkinscoieletterhea.jpg","primary":false,"translateUrl":"","linkName":"ashurstperkinscoieletterhea.jpg","type":"GRAPHIC","id":"NTFILEEy4NcyRDwSMSszJD","market":"us","size":68715}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Employee Stock Ownership","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"员工持股计划","pubTime":"2026-08-04 12:00","pubTimestamp":1785816000,"title_zh":"Form S-8 - Securities to be offered to employees in employee benefit plans","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21574366","market":"us","labels":[],"media":"sec.gov","original_id":"AN162828026052527-PCRX","pdf_url":"","pub_time":1785816000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"PCRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/0001628280-26-052527-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/pcrx-06302026x991.htm","primary":true,"translateUrl":"","linkName":"pcrx-06302026x991.htm","type":"EX-99.1","id":"NTFILEBmvSCYdHTjDun39a","market":"us","size":369452},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/pcrx-20260804.htm","primary":false,"translateUrl":"","linkName":"pcrx-20260804.htm","type":"8-K","id":"NTFILE4h8XvRkbVzZDH4K2","market":"us","size":24936},{"description":"PACIRA BIOSCIENCES LOGO","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/paciralogoa.jpg","primary":false,"translateUrl":"","linkName":"paciralogoa.jpg","type":"GRAPHIC","id":"NTFILEAZVcyhx1MZU1UY1w","market":"us","size":468777}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-08-04 12:00","pubTimestamp":1785816000,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"项目2.02：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21450393","market":"us","labels":[],"media":"sec.gov","original_id":"AN162828026046136-PCRX","pdf_url":"","pub_time":1782792000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"PCRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026046136/0001628280-26-046136-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026046136/exhibit991-ioverapressrele.htm","primary":true,"translateUrl":"","linkName":"exhibit991-ioverapressrele.htm","type":"EX-99.1","id":"NTFILEBNTNHtZAY34cqFU2","market":"us","size":24711},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026046136/pcrx-20260628.htm","primary":false,"translateUrl":"","linkName":"pcrx-20260628.htm","type":"8-K","id":"NTFILECC3XyYu8oUQYR2w2","market":"us","size":32435},{"description":"PACIRA BIOSCIENCES LOGO","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026046136/pacirabiosciencestmrgba.jpg","primary":false,"translateUrl":"","linkName":"pacirabiosciencestmrgba.jpg","type":"GRAPHIC","id":"NTFILEJDoMVoeKk3WL6H5m","market":"us","size":468777}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-06-30 12:00","pubTimestamp":1782792000,"title_zh":"Form 8-K - Current report","summary_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第1.01项：签订重大最终协议；第7.01项：法规FD披露；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21390205","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326004600-PCRX","pdf_url":"","pub_time":1781236800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"PCRX","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000195917326004600/0001959173-26-004600-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000195917326004600/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEFYaygnPMgPDsVRva","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-06-12 12:00","pubTimestamp":1781236800,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21384612","market":"us","labels":[],"media":"sec.gov","original_id":"AN162828026042525-PCRX","pdf_url":"","pub_time":1781150400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"PCRX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026042525/0001628280-26-042525-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers;\nItem 5.07: Submission of Matters to a Vote of Security Holders;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-10.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026042525/pacira2014amendedandrestat.htm","primary":true,"translateUrl":"","linkName":"pacira2014amendedandrestat.htm","type":"EX-10.1","id":"NTFILED2bfUqJQ5f9dcSYe","market":"us","size":87119},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026042525/pcrx-20260609.htm","primary":false,"translateUrl":"","linkName":"pcrx-20260609.htm","type":"8-K","id":"NTFILE3QYHmFCVHuWF2s7r","market":"us","size":53734},{"description":"EX-99.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026042525/exhibit991-agmpressrelease.htm","primary":false,"translateUrl":"","linkName":"exhibit991-agmpressrelease.htm","type":"EX-99.1","id":"NTFILEB7LrQAKrqsnGbMrS","market":"us","size":15411},{"description":"PACIRA BIOSCIENCES LOGO","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026042525/pacirabiosciencestmrgb.jpg","primary":false,"translateUrl":"","linkName":"pacirabiosciencestmrgb.jpg","type":"GRAPHIC","id":"NTFILE4He5NFET5zg4Ut8m","market":"us","size":468777}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-06-11 12:00","pubTimestamp":1781150400,"title_zh":"Form 8-K - Current report","summary_en":"Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers;\nItem 5.07: Submission of Matters to a Vote of Security Holders;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第5.02项：董事或某些高级职员的离职；选举董事；若干人员的委任：若干人员的补偿安排；项目5.07：将事项提交证券持有人表决；项目8.01：其他事件；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21383767","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326004550-PCRX","pdf_url":"","pub_time":1781150400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"PCRX","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000195917326004550/0001959173-26-004550-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000195917326004550/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEFZDFR1aL6HGhTmUv","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-06-11 12:00","pubTimestamp":1781150400,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21357010","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326004324-PCRX","pdf_url":"","pub_time":1780545600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"PCRX","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000195917326004324/0001959173-26-004324-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1296965/000195917326004324/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEH2bnjwcyXcn6a1Dh","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-06-04 12:00","pubTimestamp":1780545600,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21203121","market":"us","labels":[],"media":"sec.gov","original_id":"AN210011926001293-PCRX","pdf_url":"","pub_time":1777608000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","symbol":"PCRX","title":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","titleType":"超过5%披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000210011926001293/0002100119-26-001293-index.htm","us_notice_code":"Form SCHEDULE 13G","us_title_en":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000210011926001293/xslSCHEDULE_13G_X02/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"SCHEDULE 13G","id":"NTFILEEixfx1hR9iwpvGvL","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"超过5%披露","pubTime":"2026-05-01 12:00","pubTimestamp":1777608000,"title_zh":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21203120","market":"us","labels":[],"media":"sec.gov","original_id":"AN210012126000856-PCRX","pdf_url":"","pub_time":1777608000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","symbol":"PCRX","title":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","titleType":"超过5%披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1396814/000210012126000856/0002100121-26-000856-index.htm","us_notice_code":"Form SCHEDULE 13G","us_title_en":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000210012126000856/xslSCHEDULE_13G_X02/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"SCHEDULE 13G","id":"NTFILE6Y1H6NmrYcU9BVzh","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"超过5%披露","pubTime":"2026-05-01 12:00","pubTimestamp":1777608000,"title_zh":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21203155","market":"us","labels":[],"media":"sec.gov","original_id":"AN162828026028871-PCRX","pdf_url":"","pub_time":1777521600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"PCRX","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028871/0001628280-26-028871-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-K - PCRX - 03.31.2026","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028871/pcrx-20260331.htm","primary":true,"translateUrl":"","linkName":"pcrx-20260331.htm","type":"10-Q","id":"NTFILEGWyeRKSL6WJ6imkA","market":"us","size":1365786},{"description":"EX-10.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028871/a101paciraformofpsuagreeme.htm","primary":false,"translateUrl":"","linkName":"a101paciraformofpsuagreeme.htm","type":"EX-10.1","id":"NTFILE6PYiCAnkWwkxUGQY","market":"us","size":52209},{"description":"EX-31.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028871/pcrx-03312026xex311.htm","primary":false,"translateUrl":"","linkName":"pcrx-03312026xex311.htm","type":"EX-31.1","id":"NTFILEArAvjoapPmdTkcoK","market":"us","size":11607},{"description":"EX-31.2","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028871/pcrx-03312026xex312.htm","primary":false,"translateUrl":"","linkName":"pcrx-03312026xex312.htm","type":"EX-31.2","id":"NTFILEG2YSBE7awee5Ab6L","market":"us","size":11582},{"description":"EX-32.1","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028871/pcrx-03312026xex321.htm","primary":false,"translateUrl":"","linkName":"pcrx-03312026xex321.htm","type":"EX-32.1","id":"NTFILE5AC3z6bWpjAUbYUS","market":"us","size":8076},{"description":"PACIRA BIOSCIENCES LOGO","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028871/pcrx-20260331_g1.jpg","primary":false,"translateUrl":"","linkName":"pcrx-20260331_g1.jpg","type":"GRAPHIC","id":"NTFILE59smTiDEC7v7n6Z7","market":"us","size":82257},{"description":"PRODUCT PIPELINE","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028871/pcrx-20260331_g2.jpg","primary":false,"translateUrl":"","linkName":"pcrx-20260331_g2.jpg","type":"GRAPHIC","id":"NTFILEGZR1SAdhmFd4jMyE","market":"us","size":145898}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2026-04-30 12:00","pubTimestamp":1777521600,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.pacira.com","stockEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.4787},{"period":"3month","weight":0.4073},{"period":"6month","weight":0.4859},{"period":"1year","weight":0.6814},{"period":"ytd","weight":0.4073}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pacira BioSciences, Inc.成立于2006年12月，自2007年3月以来一直在开展与EXPAREL相关的业务。该公司是一家专注于开发、商业化和制造医药产品的专业制药公司，基于公司专有的DepoFoam给药技术，主要用于医院和门诊手术中心。该公司经营一个可报告的分部。2011年10月28日，美国食品药品监督管理局（FDA）批准了公司的新药申请，即NDA，用于公司的主要候选产品EXPAREL，一种布比卡因的脂质体注射液，一种适用于浸润到手术部位以产生术后镇痛长达72小时的酰胺型局部麻醉剂。该公司认为，EXPAREL解决了对长效非阿片类术后镇痛剂的重大未满足的医疗需求，从而简化了术后疼痛管理并减少了阿片类药物的消耗，从而改善了患者的治疗效果并提高了医院经济效益。公司发展了一支完全致力于将EXPAREL商业化的内部销售队伍，公司于2012年4月将其商业化推出。此外，继试点计划后，自2013年10月1日起，公司任命CrossLink BioScience，LLC或CrossLink作为独家第三方分销商，为期五年，在美国推广和销售用于骨科和脊柱手术的EXPAREL，但某些地理区域和账户除外，可能会根据双方协议进行变更和调整。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.04958},{"month":2,"riseRate":0.666667,"avgChangeRate":0.024537},{"month":3,"riseRate":0.5,"avgChangeRate":-0.00278},{"month":4,"riseRate":0.625,"avgChangeRate":0.045584},{"month":5,"riseRate":0.5,"avgChangeRate":0.014682},{"month":6,"riseRate":0.4375,"avgChangeRate":0.018261},{"month":7,"riseRate":0.4375,"avgChangeRate":-0.027302},{"month":8,"riseRate":0.5,"avgChangeRate":0.014523},{"month":9,"riseRate":0.3125,"avgChangeRate":-0.01285},{"month":10,"riseRate":0.3125,"avgChangeRate":0.002371},{"month":11,"riseRate":0.733333,"avgChangeRate":0.066003},{"month":12,"riseRate":0.6,"avgChangeRate":0.042036}],"exchange":"NASDAQ","name":"Pacira Pharmaceuticals","nameEN":"Pacira Pharmaceuticals"},"aProfile":null}}}